[HTML][HTML] Circulating biomarkers to monitor cancer progression and treatment
Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still,
the standard diagnostic approach relies on the analysis of a single tumor sample from a …
the standard diagnostic approach relies on the analysis of a single tumor sample from a …
Circulating cell-free DNA and colorectal cancer: a systematic review
V Vymetalkova, K Cervena, L Bartu… - International journal of …, 2018 - mdpi.com
There is a strong demand for the identification of new biomarkers in colorectal cancer (CRC)
diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably …
diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably …
Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder …
E Christensen, K Birkenkamp-Demtröder… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Novel sensitive methods for early detection of relapse and for monitoring
therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately …
therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately …
[HTML][HTML] Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare
P Mamoshina, L Ojomoko, Y Yanovich, A Ostrovski… - Oncotarget, 2018 - ncbi.nlm.nih.gov
The increased availability of data and recent advancements in artificial intelligence present
the unprecedented opportunities in healthcare and major challenges for the patients …
the unprecedented opportunities in healthcare and major challenges for the patients …
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial
BJ Noordman, BPL Wijnhoven, SM Lagarde… - Bmc Cancer, 2018 - Springer
Background Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …
MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer
Purpose: Response to preoperative chemo-radiotherapy (CRT) varies. We assessed
whether circulating tumor DNA (ctDNA) might be an early indicator of tumor response or …
whether circulating tumor DNA (ctDNA) might be an early indicator of tumor response or …
Monitoring PD-L1 expression on circulating tumor–associated cells in recurrent metastatic non–small-cell lung carcinoma predicts response to immunotherapy with …
JA Moran, DL Adams, MJ Edelman, P Lopez… - JCO precision …, 2022 - ascopubs.org
PURPOSE Current diagnostic methods to determine programmed death 1 (PD-1) receptor
and its ligand (PD-L1)/PD-1 immunotherapy (immune checkpoint inhibitor [ICI]) efficacy in …
and its ligand (PD-L1)/PD-1 immunotherapy (immune checkpoint inhibitor [ICI]) efficacy in …
Circulating tumor DNA detection: A potential tool for colorectal cancer management
H Li, C Jing, J Wu, J Ni, H Sha, X Xu… - Oncology …, 2019 - spandidos-publications.com
Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …
Circulating tumor DNA detectable in early-and late-stage colorectal cancer patients
YC Yang, D Wang, L Jin, HW Yao, JH Zhang… - Bioscience …, 2018 - portlandpress.com
Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to
limited biopsy information, impracticality of repeated biopsies, and cancer biomarker …
limited biopsy information, impracticality of repeated biopsies, and cancer biomarker …
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
PA Boonstra, TT Wind, M van Kruchten… - Cancer and Metastasis …, 2020 - Springer
Response evaluation for cancer treatment consists primarily of clinical and radiological
assessments. In addition, a limited number of serum biomarkers that assess treatment …
assessments. In addition, a limited number of serum biomarkers that assess treatment …